Board Meetings for GLENMARK
Detailed list of historic and upcoming board meetings.
| Symbol | Company | Meeting Date | Purpose | Description | Links |
|---|---|---|---|---|---|
| GLENMARK | Glenmark Pharmaceuticals Limited | 27 May 2022 | Dividend/Financial results | Board Meeting intimation for the Audited Financial Results of the Company for the quarter and Year ended March 31, 2022 and to Consider and Recommend Dividend, if any, on Equity Shares for the Year ended March 31, 2022. | |
| GLENMARK | Glenmark Pharmaceuticals Limited | 11 Feb 2022 | Financial Results | To consider and approve the financial results for the period ended December 31, 2021 | |
| GLENMARK | Glenmark Pharmaceuticals Limited | 12 Nov 2021 | Financial Results | To consider and approve the financial results for the period ended September 30, 2021 | |
| GLENMARK | Glenmark Pharmaceuticals Limited | 13 Aug 2021 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2021 | |
| GLENMARK | Glenmark Pharmaceuticals Limited | 28 May 2021 | Financial Results/Dividend | We have to inform you that, pursuant to Regulation 29 of Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015, a meeting of the Board of Directors will be held on Friday, May 28, 2021, inter alia, to consider and approve the Standalone and Consolidated Audited Financial Results of the Company for the quarter and year ended March 31, 2021 and to consider and recommend dividend, if any, on Equity Shares for the year ended March 31, 2021.��Further, as per the "Code of Conduct for Prevention of Insider Trading" and pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015 the Company has intimated its Directors and other designated persons regarding the closure of trading window from March 31, 2021 to May 30, 2021 (both days inclusive) for the purpose of approval of Audited Financial Results for the quarter and year ended March 31, 2021.���� | |
| GLENMARK | Glenmark Pharmaceuticals Limited | 12 Feb 2021 | Other business matters | Intimation of Board Meeting under Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 to consider repurchase of Foreign Currency Debt | |
| GLENMARK | Glenmark Pharmaceuticals Limited | 12 Feb 2021 | Financial Results | To consider and approve the financial results for the period ended December 31, 2020 | |
| GLENMARK | Glenmark Pharmaceuticals Limited | 06 Nov 2020 | Financial Results | To consider and approve the financial results for the period ended September 30, 2020 | |
| GLENMARK | Glenmark Pharmaceuticals Limited | 14 Aug 2020 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2020 | |
| GLENMARK | Glenmark Pharmaceuticals Limited | 26 Jun 2020 | Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2020 and dividend | |
| GLENMARK | Glenmark Pharmaceuticals Limited | 14 Feb 2020 | Financial Results | To consider and approve the financial results for the period ended December 31, 2019 | |
| GLENMARK | Glenmark Pharmaceuticals Limited | 14 Feb 2020 | Fund Raising | We have to inform you that the Board of Directors of the Company, at its meeting scheduled on February 14, 2020, will, inter-alia, consider and evaluate proposals for raising of funds either by issuance of bonds / debentures / non-convertible debt instruments or any other securities or any combination thereof, of any of the above, for refinancing of bonds/FCCBs/loans, in accordance with the FEMA ECB Guidelines, and other applicable regulations, guidelines and laws of India, and subject to all necessary regulatory, statutory and shareholder approvals, as may be required. | |
| GLENMARK | Glenmark Pharmaceuticals Limited | 14 Nov 2019 | Financial Results | To consider and approve the Unaudited Financial Results for the Second Quarter and Half Year ended September 30, 2019 | |
| GLENMARK | Glenmark Pharmaceuticals Limited | 13 Aug 2019 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2019 | |
| GLENMARK | Glenmark Pharmaceuticals Limited | 29 May 2019 | Financial Results/Dividend | We have to inform you that, pursuant to Regulation 29 of Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015, a meeting of the Board of Directors will be held on Wednesday, May 29, 2019, inter alia, to consider and approve the Standalone and Consolidated Audited Financial Results of the Company for the quarter and year ended March 31, 2019 and to consider and recommend dividend, if any, on Equity Shares for the year ended March 31, 2019.Further, as per the "Code of Conduct for Prevention of Insider Trading" and pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015 the Company has intimated its Directors and other designated persons regarding the closure of trading window from April 1, 2019 to May 31, 2019 (both days inclusive) for the purpose of approval of Standalone and Consolidated Audited Financial Results for the year ended March 31, 2019. |